Commonwealth Equity Services LLC Has $1.05 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Commonwealth Equity Services LLC trimmed its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 139,132 shares of the biotechnology company’s stock after selling 3,567 shares during the quarter. Commonwealth Equity Services LLC’s holdings in BioCryst Pharmaceuticals were worth $1,046,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Swiss National Bank lifted its holdings in shares of BioCryst Pharmaceuticals by 6.2% in the 4th quarter. Swiss National Bank now owns 386,568 shares of the biotechnology company’s stock worth $2,907,000 after purchasing an additional 22,600 shares in the last quarter. Jupiter Asset Management Ltd. grew its position in shares of BioCryst Pharmaceuticals by 10.1% during the 4th quarter. Jupiter Asset Management Ltd. now owns 1,177,929 shares of the biotechnology company’s stock valued at $8,858,000 after purchasing an additional 108,030 shares in the last quarter. Bender Robert & Associates purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $178,000. AlphaQuest LLC increased its position in shares of BioCryst Pharmaceuticals by 800.1% during the 4th quarter. AlphaQuest LLC now owns 28,442 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 25,282 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $80,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $7.50 on Tuesday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The firm has a 50-day simple moving average of $8.18 and a 200-day simple moving average of $7.82. The firm has a market cap of $1.57 billion, a P/E ratio of -12.29 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the previous year, the company posted $0.28 earnings per share. The company’s revenue was up 40.8% compared to the same quarter last year. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BCRX shares. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Evercore ISI increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.